CD274 and cancer: One mechanism of action of anti-PD-1/PD-L1 mAbs in anti-cancer treatment is to block the molecular interaction between the corresponding receptor-ligand pair, thus relieving PD-1+ T cells from PD-L1-mediated inhibition exerted by PD-L1+ tumor cells and/or myeloid cells in the tumor infiltrate (34).